Navigation Links
Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
Date:9/7/2009

PARIS and LAUSANNE, Switzerland, September 7 /PRNewswire/ -- Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.

CDC25 is a key enzyme involved in the regulation of cell cycle. Its over-expression is associated with the progression of cancer. By blocking the cell cycle and thus interrupting tumour growth, Debio 0931 represents a promising novel target for cancer therapies. This preclinical candidate will now be the subject of a full development program under the responsibility of Debiopharm.

Under the terms of the agreement Debiopharm will be exclusively responsible for the development of Debio 0931, with Ipsen having an option to re-acquire development and commercialisation rights post completion of Phase II clinical trials. Ipsen will receive an upfront payment and be eligible for milestone payments and royalties.

Jean-Luc Belingard, Ipsen's Chairman and Chief Executive Officer said: "We are delighted that Ipsen's CDC25 inhibitor will be progressed toward clinical development by Debiopharm, a company with a strong track record in oncology. Debiopharm is our long-standing partner with whom we have had a very fruitful partnership in other areas of oncology for more than 20 years and we feel confident that the full potential of CDC25 will be maximised, thanks to Debiopharm's strong expertise in oncology development."

Rolland-Yves Mauvernay, President and Founder of Debiopharm Group added: "We are extremely pleas
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
2. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
3. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Japanese Cancer Association and Debiopharm Honour Japanese Research
8. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
9. Debiopharm and EPFL Establish an Oncology Chair
10. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
11. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... (PRWEB) August 27, 2014 Flagship Biosciences ... services to the pharmaceutical and medical device industries, ... The fast growing company has consolidated its histology ... and Boulder to Westminster, CO, just north of Denver. ... Lab, 7575 W. 103rd Ave., Suite 100, Westminster, CO ...
(Date:8/27/2014)... Aug. 27, 2014 Research and Markets ... Isotope Ratio Mass Spectrometer Industry Report 2014" report ... Isotope Ratio Mass Spectrometer Industry Report 2014 is a ... the global isotope ratio mass spectrometer industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... Aug. 27, 2014 Tris Pharma, a specialty ... today announced that it has been selected as an ... Association,s 2014 Awards for Excellence competition in ... independent panel of judges from SCORE (Counselors to America,s ... will be honored at a gala event to be ...
(Date:8/27/2014)... 27, 2014 BIOEQUA, an innovative line ... use of a handheld spray, has made its EQUA ... , The brand began with an unexpected discovery ... surprised to learn that the application of nanospray technology ... and delivered directly to skin's basal layer. This resulted ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2
... Alfalight , a firm that makes high-power ... has established ties with Chinese distributor Sanetronic Company ... Hong Kong. The company was founded in 1987 as ... has eight offices in China, including Beijing, Shanghai, Shenzhen, ...
... research, nanotechnology, farm waste management and produce storage have emerged ... Transfer Award. , ,Judges for the contest have winnowed the ... The $5,000 grand prize will be presented to the winner ... in Milwaukee. , ,The finalists are: , , GHD ...
... The Joint Finance Committee rejected Governor Jim Doyle's proposal for ... The proposal, a plan to charge consumers for their music, ... several proposals turned down by the budget review panel. , ... on electronic entertainment called by some detractors the "iPod ...
Cached Biology Technology:Five remaining firms vie for Tech Transfer award 2Five remaining firms vie for Tech Transfer award 3Finance Committee rejects extra tax on Internet buys 2Finance Committee rejects extra tax on Internet buys 3
(Date:8/27/2014)... effective doses of the HIV drug maraviroc, a new ... completed before the drug was licensed in 2007, included ... key to removing maraviroc from the body. The current ... protein including nearly half of African-Americans end ... those who lack the protein even when given the ...
(Date:8/27/2014)... neural circuits in the brain of mice, scientists ... The research, led by Howard Hughes Medical Institute ... Technology (MIT), reveals that the connections between the ... about an experience and the part of the ... experience are malleable. , Altering those connections ...
(Date:8/27/2014)... to listen carefully to someone, the first thing we ... is stop moving altogether. This strategy helps us hear ... movements. , This interplay between movement and hearing also ... evidence has long suggested that the brain,s motor cortex, ... gives rise to our conscious perception of sound. , ...
Breaking Biology News(10 mins):Dosage of HIV drug may be ineffective for half of African-Americans 2Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3
... ORLANDO, Fla. Soy food consumption did not ... survivors of breast cancer, according to the results of ... 2011, held April 2-6. Researchers investigated the association ... survivors, using data from a multi-institution collaborative study, the ...
... America (ESA) has selected 37 insect-science symposia for its ... http://entsoc.org/entomology2011 ). The symposia will address important ... Disorder, insect control, invasive species, medical and veterinary entomology, ... BEES AND COLONY COLLAPSE DISORDER Bee ...
... premature aging of immune cells, which may make people more ... new UCSF-led study. The findings indicate that accelerated ... is dependent upon how long someone is depressed, particularly if ... March 2011 by the journal PLoS One and ...
Cached Biology News:Soy isoflavones not a risk for breast cancer survivors 2Entomology 2011 symposia selected 2Entomology 2011 symposia selected 3Study finds link between chronic depression and accelerated immune cell aging 2Study finds link between chronic depression and accelerated immune cell aging 3
... Rotofor purification system with PowerPac 3000 power ... separation and purification by liquid-phase isoelectric focusing ... (18 ml) and standard (60 ml) focusing ... chambers, PowerPac 3000 power supply, 10 ml ...
... Imager VersaDoc MP 4000 System is ... imaging system capable of supporting a ... fluorescence, chemiluminescence, densitometry, and chemiflourescence. ... allow imaging of multiplexed fluorescent samples, ...
...
...
Biology Products: